---
tags:
  - gp_training
urls:
  - https://www.youtube.com/watch?v=Nus61dUCJ7E
---
## 1. Big picture: what NICE actually produces
NICE doesn‚Äôt make ‚Äúone type‚Äù of guidance. It produces **different products for different jobs**:
- **Clinical practice** (what to do)
- **Funding decisions** (what the NHS must pay for)
- **Quality measurement** (what good care looks like)
- **Public health & prevention**
- **Local commissioning support**

That‚Äôs why you keep seeing **NG**, **TA**, **QS**, **Indicators**, etc.

---
## 2. Core NICE products (the ones you must know)
### üîµ 1. NICE Guidelines (**NG**)
**Example:** NG203 ‚Äì Chronic kidney disease
**What they are**
- Broad **clinical practice guidelines**
- Cover **diagnosis, monitoring, referral, management**
- Evidence-based, consensus-driven

**What they do NOT do well**
- They often **don‚Äôt give drug-by-drug eligibility**
- They may say _‚Äúconsider drug X‚Äù_ without thresholds

**Status**
- Advisory but **very influential**
- Courts, CQC, examiners treat them as gold standard

**Use them when**
- Writing management plans
- Answering exams
- Structuring GP care

---
### üü£ 2. NICE Technology Appraisals (**TA**)
**Examples:**
- TA775 ‚Äì Dapagliflozin for CKD
- TA942 ‚Äì Empagliflozin for CKD

**What they are**
- **Legal funding decisions**
- Decide whether the NHS **must provide a drug**
- Very specific inclusion/exclusion criteria

**Key point**
> If a drug has a positive TA, the NHS is **legally obliged** to fund it (within criteria)

**Why CKD SGLT2i live here**
- Because they are **new, expensive drugs**
- NG203 refers you _out_ to TAs for details

**Use them when**
- Starting expensive meds
- Challenging an ICB
- Being precise about eligibility

üìå **If NG says ‚Äúconsider‚Äù but TA says ‚Äúrecommended‚Äù ‚Üí TA wins for access**

---
### üü¢ 3. NICE Quality Standards (**QS**)
**Example:** QS5 ‚Äì CKD quality standard
**What they are**
- Short statements of **what high-quality care looks like**
- Each QS has:
    - A statement
    - A rationale
    - A measurable outcome

**Example**
> ‚ÄúPeople with CKD and ACR ‚â•3 are offered ACE inhibitors.‚Äù

**They are NOT**
- Full guidelines
- Not detailed management plans

**Use them when**
- Audits
- QOF-style thinking
- Explaining ‚Äústandard of care‚Äù

---
### üü† 4. NICE Quality Indicators
**Example:** IND322 ‚Äì CKD and SGLT2 inhibitors
**What they are**
- **Measurable metrics** derived from QS/TAs
- Used for:
    - Population health
    - Benchmarking
    - Service evaluation

**Important nuance**
- They often **operationalise** TAs
- That‚Äôs why they give **clear eGFR + ACR cut-offs**

**Why they matter clinically**
- They reveal what NICE _expects_ to be happening in practice
- They often feel more ‚Äúpractical‚Äù than NGs

üìå For CKD + SGLT2i, **IND322 is the clearest NICE document** for non-diabetics.

---
## 3. Other NICE products (know them, don‚Äôt memorise)
### üü° Public Health Guidelines (**PH**)
Now NG
- Prevention, screening, lifestyle
- e.g. smoking, obesity, physical activity
### ‚ö´ Interventional Procedures Guidance (**IPG**)
- Safety/efficacy of procedures
- Not about funding
- e.g. new surgical techniques
### üî¥ Medical Technologies Guidance (**MTG**)
- Devices, diagnostics
- e.g. monitoring tech
### üîµ Diagnostics Guidance (**DG**)
- Cost-effectiveness of diagnostic tests

---
## 4. One-table summary (bookmark this mentally)

| Type                         | Code | Purpose                                                                                          | Binding?                                                  | Example              |
| ---------------------------- | ---- | ------------------------------------------------------------------------------------------------ | --------------------------------------------------------- | -------------------- |
| Guideline                    | NG   | Clinical practice                                                                                | Advisory (strong)                                         | NG203 CKD            |
| Technology Appraisal         | TA   | Drug funding                                                                                     | **Legally binding**                                       | TA775 dapagliflozin  |
| Quality Standard             | QS   | Defines good care                                                                                | Advisory                                                  | QS5 CKD              |
| Indicator                    | IND  | Measures care delivery                                                                           | Monitoring                                                | IND322 SGLT2i in CKD |
| Public Health                | PH   | Prevention                                                                                       | Advisory                                                  | PH smoking           |
| Interventional               | IPG  | Procedures safety                                                                                | Advisory                                                  | IPG surgery          |
| Clinical Knowledge Summaries | CKS  | Practical, point-of-care clinical advice for frontline clinicians (especially GP / primary care) | ‚ÄúWhat do I do right now with the patient in front of me?‚Äù |                      |

---
# How CKS differs from NICE
| Feature                  | NICE Guidance (NG, TA, etc) | NICE CKS                    |
| ------------------------ | --------------------------- | --------------------------- |
| Level                    | High-level recommendations  | Practical step-by-step care |
| Focus                    | What _should_ be done       | How to _actually do it_     |
| Includes dosing?         | Often no                    | **Yes**                     |
| Includes safety-netting? | Sometimes                   | **Always**                  |
| Primary care-specific    | Mixed                       | **Yes**                     |
| Medicolegal weight       | High                        | Supportive, not binding     |
CKS interprets and operationalises NICE guidance (plus other evidence like SIGN, RCGP, BNF).

---
## 5. How _you_ should use these in practice (GP lens)
- **Exams / teaching** ‚Üí **NG**
- **Starting new expensive drugs** ‚Üí **TA**
- **Audits / QOF / ARRS logic** ‚Üí **QS + Indicators**
- **‚ÄúWhy is the ICB asking for this?‚Äù** ‚Üí **Indicators**
- **Disputes about funding** ‚Üí **TA (always wins)**

---
## 6. CKD + SGLT2i example (pulling it together)
- NG203 ‚Üí says SGLT2i are part of CKD management    
- TA775 / TA942 ‚Üí legally approve use in **non-diabetic CKD** & say the NHS must fund them
- [IND322](https://www.nice.org.uk/indicators/ind322-kidney-conditions-ckd-and-sglt-2-inhibitors) ‚Üí tells services **exactly which patients** should be on them
- **CKS CKD** ‚Üí tells you:
    - when to consider them
    - how to start
    - what to monitor
    - what to warn patients about

CKS is where the **‚Äúhow‚Äù** lives. That‚Äôs why **the detail lives outside the NG**.